Dangers of rosuvastatin identified before and after FDA approval

Lancet. 2004 Jun 26;363(9427):2189-90. doi: 10.1016/S0140-6736(04)16513-6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Drug Approval*
  • Fluorobenzenes / adverse effects*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Muscular Diseases / chemically induced
  • Pyrimidines / adverse effects*
  • Renal Insufficiency / chemically induced
  • Rhabdomyolysis / chemically induced
  • Rosuvastatin Calcium
  • Sulfonamides / adverse effects*
  • United States
  • United States Food and Drug Administration

Substances

  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrimidines
  • Sulfonamides
  • Rosuvastatin Calcium